This review focuses on the latest advances in our understanding regarding the crosstalk of Wnt5a-ROR1 and Hippo-YAP/TAZ or BMI-1 in tumorigenesis and drug resistance and discusses novel strategies for the therapeutic targeting of ROR1 in cancer treatment. Here, ROR1 is linked to cancer.